{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T20:42:17Z","timestamp":1794256937984,"version":"4.9.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:00:00Z","timestamp":1726012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:00:00Z","timestamp":1726012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82270177"],"award-info":[{"award-number":["82270177"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biomark Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Acute myeloid leukemia (AML), as the most common subtype of leukemia in adults, is characterised by rapid progression and poor prognosis. In the context of the rapid development of medical technology and the complexity of social factors, a detailed report describing the latest epidemiological patterns of AML is important for decision makers to allocate healthcare resources effectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Our research utilized the latest data sourced from the Global Burden of Disease (GBD) 2021. To delineate the burden of AML, we comprehensively described the incidence, deaths, disability-adjusted life years (DALYs), and the associated age-standardized rates per 100,000 persons (ASR) spanning from 1990 to 2021 stratifies according to age, sex, socio-demographic index (SDI), and nationality. Additionally, we extracted and analyzed data about the risk factors that contribute to AML-related deaths and DALYs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>According to our study, the incidence of AML has continued to rise globally from 79,372 in 1990 to 144,645 in 2021 and AML affected the male and the elderly populations disproportionately. Furthermore, there was a significant positive correlation between the burden of AML and the SDI value. Developed nations generally exhibited higher age-standardized incidence rate, age-standardized death rate, and age-standardized disability-adjusted life year rate than the developing nations. We also analyzed the prevalence of smoking, high body mass index, and occupational benzene and formaldehyde exposure in the AML population in different SDI regions. Moreover, smoking and high body mass index were more prevalent in developed countries, whereas occupational exposure to these chemicals was the predominant risk factor in developing countries.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The global burden of AML has increased over the past 32 years, with rising morbidity and mortality. The incidence of AML is differentially distributed across different SDI countries or regions. AML incidence is higher in the elderly and in men. The proportions of smoking, high body mass index, and occupational exposure to benzene and formaldehyde varied by region. The findings highlight the need for region-specific prevention and call for future research on preventive strategies and new treatments to lower AML incidence and improve patient outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40364-024-00649-y","type":"journal-article","created":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T23:31:03Z","timestamp":1726011063000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":114,"title":["Global, regional, and national burden of acute myeloid leukemia, 1990\u20132021: a systematic analysis for the global burden of disease study 2021"],"prefix":"10.1186","volume":"12","author":[{"given":"Yeming","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiqin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoya","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingxin","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7629-2642","authenticated-orcid":false,"given":"Dengju","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,11]]},"reference":[{"key":"649_CR1","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374:2209\u201321.","journal-title":"N Engl J Med"},{"key":"649_CR2","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/S0140-6736(23)00108-3","volume":"401","author":"CD DiNardo","year":"2023","unstructured":"DiNardo CD, Erba HP, Freeman SD, Wei AH. Acute myeloid leukaemia. Lancet. 2023;401:2073\u201386.","journal-title":"Lancet"},{"key":"649_CR3","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/s41586-018-0317-6","volume":"559","author":"S Abelson","year":"2018","unstructured":"Abelson S, Collord G, Ng SWK, Weissbrod O, Mendelson Cohen N, Niemeyer E, et al. Prediction of acute myeloid leukaemia risk in healthy individuals. Nature. 2018;559:400\u20134.","journal-title":"Nature"},{"key":"649_CR4","doi-asserted-by":"crossref","unstructured":"Komp-Leukkunen K, Sarasma J. Social sustainability in aging populations: a systematic literature review. Gerontologist. 2024;64.","DOI":"10.1093\/geront\/gnad097"},{"key":"649_CR5","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1111\/bjh.16667","volume":"190","author":"D Kristensen","year":"2020","unstructured":"Kristensen D, Nielsen LB, Roug AS, Kristensen TC, El-Galaly TC, N\u00f8rgaard JM, et al. The prognostic effect of smoking status on intensively treated acute myeloid leukaemia - a Danish nationwide cohort study. Br J Haematol. 2020;190:236\u201343.","journal-title":"Br J Haematol"},{"key":"649_CR6","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.leukres.2011.12.020","volume":"36","author":"JJ Castillo","year":"2012","unstructured":"Castillo JJ, Reagan JL, Ingham RR, Furman M, Dalia S, Merhi B, et al. Obesity but not overweight increases the incidence and mortality of leukemia in adults: a meta-analysis of prospective cohort studies. Leuk Res. 2012;36:868\u201375.","journal-title":"Leuk Res"},{"key":"649_CR7","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1476-069X-9-31","volume":"9","author":"A Khalade","year":"2010","unstructured":"Khalade A, Jaakkola MS, Pukkala E, Jaakkola JJ. Exposure to benzene at work and the risk of leukemia: a systematic review and meta-analysis. Environ Health. 2010;9:31.","journal-title":"Environ Health"},{"key":"649_CR8","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1093\/carcin\/bgu229","volume":"36","author":"Q Lan","year":"2015","unstructured":"Lan Q, Smith MT, Tang X, Guo W, Vermeulen R, Ji Z, et al. Chromosome-wide aneuploidy study of cultured circulating myeloid progenitor cells from workers occupationally exposed to formaldehyde. Carcinogenesis. 2015;36:160\u20137.","journal-title":"Carcinogenesis"},{"key":"649_CR9","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13045-023-01419-3","volume":"16","author":"Z Yu","year":"2023","unstructured":"Yu Z, Li J, Wen X, Han Y, Jiang P, Zhu M, et al. AMLnet, a deep-learning pipeline for the differential diagnosis of acute myeloid leukemia from bone marrow smears. J Hematol Oncol. 2023;16:27.","journal-title":"J Hematol Oncol"},{"key":"649_CR10","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391\u2013405.","journal-title":"Blood"},{"key":"649_CR11","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345\u201377.","journal-title":"Blood"},{"key":"649_CR12","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/s41408-021-00514-3","volume":"11","author":"M Yilmaz","year":"2021","unstructured":"Yilmaz M, Kantarjian H, Ravandi F. Acute promyelocytic leukemia current treatment algorithms. Blood Cancer J. 2021;11:123.","journal-title":"Blood Cancer J"},{"key":"649_CR13","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1182\/blood.V98.6.1752","volume":"98","author":"PD Kottaridis","year":"2001","unstructured":"Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton AA, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood. 2001;98:1752\u20139.","journal-title":"Blood"},{"key":"649_CR14","doi-asserted-by":"publisher","first-page":"3589","DOI":"10.1182\/blood.V97.11.3589","volume":"97","author":"DL Stirewalt","year":"2001","unstructured":"Stirewalt DL, Kopecky KJ, Meshinchi S, Appelbaum FR, Slovak ML, Willman CL, Radich JP. FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood. 2001;97:3589\u201395.","journal-title":"Blood"},{"key":"649_CR15","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1200\/JCO.22.00715","volume":"41","author":"T Grob","year":"2023","unstructured":"Grob T, Sanders MA, Vonk CM, Kavelaars FG, Rijken M, Hanekamp DW, et al. Prognostic value of FLT3-internal tandem duplication residual disease in acute myeloid leukemia. J Clin Oncol. 2023;41:756\u201365.","journal-title":"J Clin Oncol"},{"key":"649_CR16","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.annonc.2022.11.004","volume":"34","author":"A Bazinet","year":"2023","unstructured":"Bazinet A, Kantarjian HM. Moving toward individualized target-based therapies in acute myeloid leukemia. Ann Oncol. 2023;34:141\u201351.","journal-title":"Ann Oncol"},{"key":"649_CR17","doi-asserted-by":"crossref","unstructured":"DiNardo KW, LeBlanc TW, Chen H. Novel agents and regimens in acute myeloid leukemia: latest updates from 2022 ASH annual meeting. J Hematol Oncol. 2023;16:17.","DOI":"10.1186\/s13045-023-01411-x"},{"key":"649_CR18","doi-asserted-by":"crossref","unstructured":"Wienecke CP, Heida B, Venturini L, Gabdoulline R, Kr\u00fcger K, Teich K et al. Clonal relapse dynamics in acute myeloid leukemia following allogeneic hematopoietic cell transplantation. Blood. 2024.","DOI":"10.1182\/blood.2023022697"},{"key":"649_CR19","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.tips.2024.03.005","volume":"45","author":"M Forsberg","year":"2024","unstructured":"Forsberg M, Konopleva M. AML treatment: conventional chemotherapy and emerging novel agents. Trends Pharmacol Sci. 2024;45:430\u201348.","journal-title":"Trends Pharmacol Sci"},{"key":"649_CR20","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1080\/10428194.2020.1855339","volume":"62","author":"L Ning","year":"2021","unstructured":"Ning L, Li D, Lu P, Que Y. Exploring the determinants that influence hospital costs of induction therapy for acute myeloid leukemia. Leuk Lymphoma. 2021;62:1211\u20138.","journal-title":"Leuk Lymphoma"},{"key":"649_CR21","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1080\/14787210.2020.1820863","volume":"19","author":"AM Peseski","year":"2021","unstructured":"Peseski AM, McClean M, Green SD, Beeler C, Konig H. Management of fever and neutropenia in the adult patient with acute myeloid leukemia. Expert Rev Anti Infect Ther. 2021;19:359\u201378.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"649_CR22","doi-asserted-by":"publisher","first-page":"e34","DOI":"10.1016\/S2352-3026(17)30228-4","volume":"5","author":"M Mittelman","year":"2018","unstructured":"Mittelman M, Platzbecker U, Afanasyev B, Grosicki S, Wong RSM, Anagnostopoulos A, et al. Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial. Lancet Haematol. 2018;5:e34\u201343.","journal-title":"Lancet Haematol"},{"key":"649_CR23","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13045-020-00908-z","volume":"13","author":"M Yi","year":"2020","unstructured":"Yi M, Li A, Zhou L, Chu Q, Song Y, Wu K. The global burden and attributable risk factor analysis of acute myeloid leukemia in 195 countries and territories from 1990 to 2017: estimates based on the global burden of disease study 2017. J Hematol Oncol. 2020;13:72.","journal-title":"J Hematol Oncol"},{"key":"649_CR24","doi-asserted-by":"publisher","first-page":"e2300229","DOI":"10.1200\/GO.23.00229","volume":"9","author":"CT Jani","year":"2023","unstructured":"Jani CT, Ahmed A, Singh H, Mouchati C, Al Omari O, Bhatt PS, et al. Burden of AML, 1990\u20132019: estimates from the global burden of disease study. JCO Glob Oncol. 2023;9:e2300229.","journal-title":"JCO Glob Oncol"},{"key":"649_CR25","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1016\/S0140-6736(24)00367-2","volume":"403","author":"Global burden","year":"2024","unstructured":"Global burden. Of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990\u20132021: a systematic analysis for the global burden of disease study 2021. Lancet. 2024;403:2100\u201332.","journal-title":"Lancet"},{"key":"649_CR26","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1016\/S0140-6736(24)00757-8","volume":"403","author":"Global incidence","year":"2024","unstructured":"Global incidence. Prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990\u20132021: a systematic analysis for the global burden of disease study 2021. Lancet. 2024;403:2133\u201361.","journal-title":"Lancet"},{"key":"649_CR27","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1016\/S0140-6736(24)00933-4","volume":"403","author":"Global burden and strength of evidence for","year":"2024","unstructured":"Global burden and strength of evidence for. 88 risk factors in 204 countries and 811 subnational locations, 1990\u20132021: a systematic analysis for the global burden of disease study 2021. Lancet. 2024;403:2162\u2013203.","journal-title":"Lancet"},{"key":"649_CR28","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1001\/jamaoncol.2016.5688","volume":"3","author":"C Fitzmaurice","year":"2017","unstructured":"Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol. 2017;3:524\u201348.","journal-title":"JAMA Oncol"},{"key":"649_CR29","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/bph.16149","volume":"181","author":"HA Ogana","year":"2024","unstructured":"Ogana HA, Hurwitz S, Wei N, Lee E, Morris K, Parikh K, Kim YM. Targeting integrins in drug-resistant acute myeloid leukaemia. Br J Pharmacol. 2024;181:295\u2013316.","journal-title":"Br J Pharmacol"},{"key":"649_CR30","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1111\/bjh.19121","volume":"203","author":"E Herrity","year":"2023","unstructured":"Herrity E, Pereira MP, Kim DDH. Acute myeloid leukaemia relapse after allogeneic haematopoietic stem cell transplantation: mechanistic diversity and therapeutic directions. Br J Haematol. 2023;203:722\u201335.","journal-title":"Br J Haematol"},{"key":"649_CR31","doi-asserted-by":"publisher","first-page":"1329529","DOI":"10.3389\/fpubh.2023.1329529","volume":"11","author":"P Chen","year":"2023","unstructured":"Chen P, Liu X, Zhao Y, Hu Y, Guo J, Wang H. Global, national, and regional burden of acute myeloid leukemia among 60\u201389 years-old individuals: insights from a study covering the period 1990 to 2019. Front Public Health. 2023;11:1329529.","journal-title":"Front Public Health"},{"key":"649_CR32","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1002\/cac2.12094","volume":"40","author":"Z Ou","year":"2020","unstructured":"Ou Z, Yu D, Liang Y, He W, Li Y, Zhang M, et al. Analysis of the global burden of disease study highlights the trends in death and disability-adjusted life years of leukemia from 1990 to 2017. Cancer Commun (Lond). 2020;40:598\u2013610.","journal-title":"Cancer Commun (Lond)"},{"key":"649_CR33","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","volume":"36","author":"RM Shallis","year":"2019","unstructured":"Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM. Epidemiology of acute myeloid leukemia: recent progress and enduring challenges. Blood Rev. 2019;36:70\u201387.","journal-title":"Blood Rev"},{"key":"649_CR34","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s10552-004-7115-1","volume":"16","author":"K Kasim","year":"2005","unstructured":"Kasim K, Levallois P, Abdous B, Auger P, Johnson KC. Lifestyle factors and the risk of adult leukemia in Canada. Cancer Causes Control. 2005;16:489\u2013500.","journal-title":"Cancer Causes Control"},{"key":"649_CR35","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1097\/COC.0b013e3181dea934","volume":"34","author":"MM Byrne","year":"2011","unstructured":"Byrne MM, Halman LJ, Koniaris LG, Cassileth PA, Rosenblatt JD, Cheung MC. Effects of poverty and race on outcomes in acute myeloid leukemia. Am J Clin Oncol. 2011;34:297\u2013304.","journal-title":"Am J Clin Oncol"},{"key":"649_CR36","doi-asserted-by":"crossref","unstructured":"Guadamuz JS, Wang X, Ryals CA, Miksad RA, Snider J, Walters J, Calip GS. Socioeconomic status and inequities in treatment initiation and survival among patients with cancer, 2011\u20132022. JNCI Cancer Spectr. 2023;7.","DOI":"10.1093\/jncics\/pkad058"},{"key":"649_CR37","doi-asserted-by":"crossref","unstructured":"Mahmood MN, Dhakal SP. Ageing population and society: a scientometric analysis. Qual Quant. 2022:1\u201318.","DOI":"10.1007\/s11135-022-01509-3"},{"key":"649_CR38","doi-asserted-by":"publisher","first-page":"107409","DOI":"10.1016\/j.envint.2022.107409","volume":"167","author":"FM Onyije","year":"2022","unstructured":"Onyije FM, Olsson A, Erdmann F, Magnani C, Petridou E, Clavel J, et al. Parental occupational exposure to combustion products, metals, silica and asbestos and risk of childhood leukaemia: findings from the Childhood Cancer and Leukaemia International Consortium (CLIC). Environ Int. 2022;167:107409.","journal-title":"Environ Int"},{"key":"649_CR39","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.apsb.2021.09.015","volume":"12","author":"M Liao","year":"2022","unstructured":"Liao M, Chen R, Yang Y, He H, Xu L, Jiang Y, et al. Aging-elevated inflammation promotes DNMT3A R878H-driven clonal hematopoiesis. Acta Pharm Sin B. 2022;12:678\u201391.","journal-title":"Acta Pharm Sin B"},{"key":"649_CR40","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/s41577-023-00843-3","volume":"23","author":"R Belizaire","year":"2023","unstructured":"Belizaire R, Wong WJ, Robinette ML, Ebert BL. Clonal haematopoiesis and dysregulation of the immune system. Nat Rev Immunol. 2023;23:595\u2013610.","journal-title":"Nat Rev Immunol"},{"key":"649_CR41","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1182\/blood.2019004770","volume":"135","author":"RP Hasserjian","year":"2020","unstructured":"Hasserjian RP, Steensma DP, Graubert TA, Ebert BL. Clonal hematopoiesis and measurable residual disease assessment in acute myeloid leukemia. Blood. 2020;135:1729\u201338.","journal-title":"Blood"},{"key":"649_CR42","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.beha.2019.05.007","volume":"32","author":"P Desai","year":"2019","unstructured":"Desai P, Hassane D, Roboz GJ. Clonal hematopoiesis and risk of acute myeloid leukemia. Best Pract Res Clin Haematol. 2019;32:177\u201385.","journal-title":"Best Pract Res Clin Haematol"},{"key":"649_CR43","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1158\/2159-8290.CD-19-1011","volume":"10","author":"NJ Short","year":"2020","unstructured":"Short NJ, Konopleva M, Kadia TM, Borthakur G, Ravandi F, DiNardo CD, Daver N. Advances in the treatment of acute myeloid leukemia: new drugs and new challenges. Cancer Discov. 2020;10:506\u201325.","journal-title":"Cancer Discov"},{"key":"649_CR44","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1002\/ajh.25978","volume":"95","author":"E Morsia","year":"2020","unstructured":"Morsia E, McCullough K, Joshi M, Cook J, Alkhateeb HB, Al-Kali A, et al. Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients. Am J Hematol. 2020;95:1511\u201321.","journal-title":"Am J Hematol"},{"key":"649_CR45","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41409-021-01476-7","volume":"57","author":"DA Pollyea","year":"2022","unstructured":"Pollyea DA, Winters A, McMahon C, Schwartz M, Jordan CT, Rabinovitch R, et al. Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML patients older than 60. Bone Marrow Transpl. 2022;57:160\u20136.","journal-title":"Bone Marrow Transpl"},{"key":"649_CR46","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1182\/blood.2022016362","volume":"141","author":"NG Daver","year":"2023","unstructured":"Daver NG, Dail M, Garcia JS, Jonas BA, Yee KWL, Kelly KR, et al. Venetoclax and idasanutlin in relapsed\/refractory AML: a nonrandomized, open-label phase 1b trial. Blood. 2023;141:1265\u201376.","journal-title":"Blood"},{"key":"649_CR47","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1002\/cncr.34780","volume":"129","author":"VH Duong","year":"2023","unstructured":"Duong VH, Ruppert AS, Mims AS, Borate U, Stein EM, Baer MR, et al. Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: a phase 2 substudy of the beat AML master trial. Cancer. 2023;129:2308\u201320.","journal-title":"Cancer"},{"key":"649_CR48","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1002\/cncr.33477","volume":"127","author":"HM Kantarjian","year":"2021","unstructured":"Kantarjian HM, Kadia TM, DiNardo CD, Welch MA, Ravandi F. Acute myeloid leukemia: treatment and research outlook for 2021 and the MD Anderson approach. Cancer. 2021;127:1186\u2013207.","journal-title":"Cancer"},{"key":"649_CR49","doi-asserted-by":"crossref","unstructured":"Gurnari C, Pagliuca S, Visconte V. Deciphering the therapeutic resistance in acute myeloid leukemia. Int J Mol Sci. 2020;21.","DOI":"10.3390\/ijms21228505"},{"key":"649_CR50","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.2147\/OTT.S191621","volume":"12","author":"J Zhang","year":"2019","unstructured":"Zhang J, Gu Y, Chen B. Mechanisms of drug resistance in acute myeloid leukemia. Onco Targets Ther. 2019;12:1937\u201345.","journal-title":"Onco Targets Ther"},{"key":"649_CR51","doi-asserted-by":"publisher","first-page":"100760","DOI":"10.1016\/j.blre.2020.100760","volume":"47","author":"RM Shallis","year":"2021","unstructured":"Shallis RM, Weiss JJ, Deziel NC, Gore SD. Challenging the concept of de novo acute myeloid leukemia: environmental and occupational leukemogens hiding in our midst. Blood Rev. 2021;47:100760.","journal-title":"Blood Rev"},{"key":"649_CR52","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.critrevonc.2016.01.003","volume":"99","author":"V Colamesta","year":"2016","unstructured":"Colamesta V, D\u2019Aguanno S, Breccia M, Bruffa S, Cartoni C, La Torre G. Do the smoking intensity and duration, the years since quitting, the methodological quality and the year of publication of the studies affect the results of the meta-analysis on cigarette smoking and acute myeloid leukemia (AML) in adults? Crit Rev Oncol Hematol. 2016;99:376\u201388.","journal-title":"Crit Rev Oncol Hematol"},{"key":"649_CR53","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1080\/10408444.2024.2337435","volume":"54","author":"LA Cox Jr","year":"2024","unstructured":"Cox LA Jr., Thompson WJ, Mundt KA. Interventional probability of causation (IPoC) with epidemiological and partial mechanistic evidence: benzene vs. formaldehyde and acute myeloid leukemia (AML). Crit Rev Toxicol. 2024;54:252\u201389.","journal-title":"Crit Rev Toxicol"},{"key":"649_CR54","doi-asserted-by":"publisher","first-page":"17998","DOI":"10.1038\/s41598-017-18278-x","volume":"7","author":"S Li","year":"2017","unstructured":"Li S, Chen L, Jin W, Ma X, Ma Y, Dong F, et al. Influence of body mass index on incidence and prognosis of acute myeloid leukemia and acute promyelocytic leukemia: a meta-analysis. Sci Rep. 2017;7:17998.","journal-title":"Sci Rep"},{"key":"649_CR55","doi-asserted-by":"publisher","first-page":"100736","DOI":"10.1016\/j.blre.2020.100736","volume":"47","author":"RM Shallis","year":"2021","unstructured":"Shallis RM, Weiss JJ, Deziel NC, Gore SD. A clandestine culprit with critical consequences: benzene and acute myeloid leukemia. Blood Rev. 2021;47:100736.","journal-title":"Blood Rev"},{"key":"649_CR56","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1093\/jnci\/djy143","volume":"111","author":"MS Linet","year":"2019","unstructured":"Linet MS, Gilbert ES, Vermeulen R, Dores GM, Yin SN, Portengen L, et al. Benzene exposure response and risk of myeloid neoplasms in Chinese workers: a multicenter case-cohort study. J Natl Cancer Inst. 2019;111:465\u201374.","journal-title":"J Natl Cancer Inst"},{"key":"649_CR57","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1097\/JOM.0000000000000466","volume":"57","author":"H Checkoway","year":"2015","unstructured":"Checkoway H, Dell LD, Boffetta P, Gallagher AE, Crawford L, Lees PS, Mundt KA. Formaldehyde exposure and mortality risks from acute myeloid leukemia and other lymphohematopoietic malignancies in the US National Cancer Institute cohort study of workers in formaldehyde industries. J Occup Environ Med. 2015;57:785\u201394.","journal-title":"J Occup Environ Med"},{"key":"649_CR58","doi-asserted-by":"crossref","unstructured":"Adamovi\u0107 D, \u010cepi\u0107 Z, Adamovi\u0107 S, Sto\u0161i\u0107 M, Obrovski B, Mora\u010da S, Vojinovi\u0107 Miloradov M. Occupational exposure to formaldehyde and cancer risk assessment in an anatomy laboratory. Int J Environ Res Public Health. 2021;18.","DOI":"10.3390\/ijerph182111198"},{"key":"649_CR59","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1007\/s00277-022-04812-z","volume":"101","author":"X Bi","year":"2022","unstructured":"Bi X, French Z, Palmisiano N, Wen KY, Wilde L. The prognostic impact of cigarette smoking on survival in acute myeloid leukemia with TP53 mutations and\/or 17p deletions. Ann Hematol. 2022;101:1251\u20139.","journal-title":"Ann Hematol"},{"key":"649_CR60","first-page":"10049","volume":"23","author":"H Shi","year":"2019","unstructured":"Shi H, Shao X, Hong Y. Association between cigarette smoking and the susceptibility of acute myeloid leukemia: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci. 2019;23:10049\u201357.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"649_CR61","doi-asserted-by":"publisher","first-page":"E125","DOI":"10.1002\/ajh.23744","volume":"89","author":"S Fircanis","year":"2014","unstructured":"Fircanis S, Merriam P, Khan N, Castillo JJ. The relation between cigarette smoking and risk of acute myeloid leukemia: an updated meta-analysis of epidemiological studies. Am J Hematol. 2014;89:E125\u201332.","journal-title":"Am J Hematol"},{"key":"649_CR62","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1002\/hon.2457","volume":"36","author":"T Ugai","year":"2018","unstructured":"Ugai T, Matsuo K, Oze I, Ito H, Wakai K, Wada K, et al. Smoking and subsequent risk of acute myeloid leukaemia: a pooled analysis of 9 cohort studies in Japan. Hematol Oncol. 2018;36:262\u20138.","journal-title":"Hematol Oncol"},{"key":"649_CR63","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1016\/S0140-6736(24)00476-8","volume":"403","author":"Global age-sex","year":"2024","unstructured":"Global age-sex. -specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950\u20132021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the global burden of Disease Study 2021. Lancet. 2024;403:1989\u20132056.","journal-title":"Lancet"}],"container-title":["Biomarker Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-024-00649-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40364-024-00649-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-024-00649-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:09:19Z","timestamp":1726013359000},"score":1,"resource":{"primary":{"URL":"https:\/\/biomarkerres.biomedcentral.com\/articles\/10.1186\/s40364-024-00649-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,11]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["649"],"URL":"https:\/\/doi.org\/10.1186\/s40364-024-00649-y","relation":{},"ISSN":["2050-7771"],"issn-type":[{"value":"2050-7771","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,11]]},"assertion":[{"value":"24 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"101"}}